|
Welcome, New SoCalBio Members
| |
|
Join SoCalBio
Join SoCalBio leaders to promote the biotech and device industries in Los Angeles, Orange County and neighboring communities for job creation and overall economic growth.
|  |
| Thanks to SoCalBio Media Partners
|
|
|
January 30, 2012 
|  Editor: Ahmed Enany
President & CEO
Southern California
Biomedical Council
enany@socalbio.org
www.socalbio.org
|
| Hot off the Press | Valeant Pharmaceuticals Withdraws Offer for Acquisition of ISTA Pharmaceuticals Inc.
"As we stated last December, we were not interested in participating in a lengthy evaluation process and we are disappointed that the ISTA team was not willing to fully explore our proposal by January 31," stated J. Michael Pearson, chairman and chief executive officer of Valeant ... Read Valeant's press release |
| RSVP Now |
 February 14, 11:30 am to 1:30 pm at RSK Designs in Thousand Oaks:
SoCalBio Executive Luncheon and Roundtable Discussion in Ventura County (By Invitation Only)... Click here for more info and to RSVP  February 16, 4:00 to 7:00 pm at the Alfred Mann Foundation in Santa Clarita:
SoCalBio Women, Work & Wisdom (W3) Mixer in Los Angeles. Elena Medo of Neolac (Murrrieta) and Shenda Baker of Synedgen (Claremont) will speak about "Overcoming Startup Company Challenges" (By Invitation Only).. . Click here for more info and to RSVP  February 23, 7:00 to 9:30 am at UCI University Club in Irvine:
|
 | |
Click on image for more info
|
|
| Featured Video | |
David Agus and The End of Illness
David Agus, a professor of medicine and engineering at University of Southern California, has some provocative ideas regarding the treatment of cancer after a few decades of research in the field. Recently. he released his controversial book, The End of Illness, and here's the talk he gave at TEDMED
 | | David Agus at TEDMED 2011 |
|
| Biotech Funding | |
Is There Really an Early-Stage Bioscience Company Funding Drought?
 In his Forbes Magazine blog, venture capitalist Bruce Booth (photo right) contends that recent data about venture funding in the US "don't cry out that biotechs are hurting, shriveling, or suffering immensely." He contends that the 2011 data of VC funding of biotechnology show that "there's an ecosystem here that works: it funds ~100 new startups a year, not a bad pace of venture formation" .... Read more at Forbes
|
| SoCalBio Helps You Save Money | |
Companies utilizing the SoCalBio Group Purchasing Program enjoy significant savings on products and services procured through this program. Here are the actual savings generated from the SoCalBio-VWR program for lab equipment and supplies:
|
Lab Supplies Spend Range Under SoCalBio-VWR Program
| Average Savings Off List Price Under SoCalBio-VWR Program | | > $2M | $2,682,800 | | $1M - $2M | $931,959 | | $500k - $1M | $472,161 | | $250k - $500k | $252,683 | | $100k - $250k | $108,145 | | $50k - $100k | $53,582 | | $25k - $50k | $23,812 | | $10k - $25k | $12,304 | | < $10k | $2,696 |
The savings represent average annual savings of the actual program participants in the BIO-VWR program. Results will vary based on individual company's Product Mix and Purchase Volume ... Learn more
|
| Under the SpotLight | |
Uptake Medical (Tustin)
The Future of InterVapor: Q&A with Uptake's Chief Medical Officer Steven Kesten
 InterVapor, from Uptake Medical (Tustin, CA), is a non-surgical endoscopic lung volume reduction procedure that uses thermal ablation without leaving foreign materials in the lung. In clinical studies of patients with severe emphysema, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life. Read interview with Steven Kesten, Chief Medical Officer at Uptake Medical, at Medgadget
|
| New Patent | The Culver City-Based Sofie Biosciences Is Awarded a US Patent on [18F]FAC, a Probe for Use in Oncology and Immunology
 "[18F]FAC is a remarkable imaging probe. It specifically targets a single enzyme, dCK, and when that target is removed, the signal is absent. [18F]FAC displays rapid in vivo transport into cells, dCK dependent accumulation, sufficient in vivo stability, and because of trace amounts of [18F]FAC used, no evidence has been found for neither pharmacologic effects nor the toxicity in humans. Making [18F]FAC available for broad use in both academic and commercial research communities is the next step in the milestones of the imaging probe segment of Sofie's business" said Patrick Phelps, Sofie's President and CEO ... Read Press Relese
|
| M&As |  Amgen to Buy Micromet for $1.6 Billion
Micromet, which currently has no drugs on the market, designs cancer therapies that target blood and solid tumor cancers, including leukemia and non-Hodgkin's lymphomas. The company has research facilities in Munich and is based in Rockville, Md ...Read more at the New York Times
|
| SoCalBio Sponsored | | 
Ecosystem of an Entrepreneurial UCLA
Monday, January 30, 2012
3:30-5:30pm
CNSI Auditorium
Free event but pre-registration is a MUST
|
|
| Generic Drugs | | Amphastar Wins Stay on Lovenox in its Legal Battle with Momenta Pharmaceuticals
 Last week, the U.S. Court of Appeals for the Federal Circuit granted the Rancho Cucamonga-based Amphastar Pharmaceuticals Inc. and its Partner Watson Pharmaceuticals a stay of an October, 2011 order that prevented sales of a generic version of Momenta's blood thinner Lovenox. The court, which heard an appeal of the order, gave no reason for its decision in the stay. Watson and Amphastar announced plan to begin sales immediately ... Read more at Bloomberg |
Jobs Available
| | Physician Therapeutics (Los Angeles)
|
|
| About SoCalBio |
 SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
|
|
